Arvinas Shareholder Letter
John Houston, Chairperson, CEO and President at Arvinas, shared on LinkedIn:
“We recently released the Arvinas 2023 Annual Report, which summarized our triumphs and milestones throughout the year.
Among its highlights is a letter to our shareholders, which describes our commitment and gratitude to our patients and shareholders.
I’m excited to share a portion of this letter here on my blog, summarizing the strides we’ve made and the vision that propels us forward. Read below for more!”
He further added:
“In 2023, we continued to execute on our mission to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform.
We have executed across our clinical and corporate objectives and leveraged key milestones to ensure that Arvinas is well positioned for near- and long-term success.
During the year, we generated important data across our preclinical and clinical programs that allowed us to advance and prioritize our broad pipeline of targets in oncology and neurology.
We reported promising data from late-stage clinical programs and progressed key assets in early-stage development. Our PROTAC Discovery Engine continued to expand the application of protein degradation and has set the stage for another year of growth in 2024.
As we push forward our pursuit of PROTAC degraders in multiple therapeutic areas, our organization has continued to evolve.
Key additions to our team last year included Kelly Page, who joined as a Senior Vice President and heads Global Oncology Strategy and Program Leadership.
Ms. Page’s depth of experience in commercializing oncology therapeutics will be invaluable as we progress our late-stage programs and she has already proven herself to be a tremendous asset to our team.
We additionally note that Timothy Shannon, M.D., former Chairperson and member of the Board of Directors since 2013, decided to step down in June after a decade of championing Arvinas as a highly valued and trusted business partner.
We commend Tim for his contributions and thank him for his years of support.
To close, I want to extend my gratitude to all Arvinas employees for their unwavering commitment to our mission.
We are turning targeted protein degradation into one of the most promising areas of medical research and challenging the perceived limits of drug discovery.
The Arvinas team is highly motivated and completely focused on developing a new class of medicines that aims to be transformative for patients, their families, and their health care providers.
I am also grateful to our stockholders and collaborators, who enable our progress towards bringing potential therapeutics to patients.
Most of all, I thank the patients who participate in our trials, as their trust and support is critical to all of our past, current, and future accomplishments.
John Houston, Ph.D. .
Chairperson, Chief Executive Officer and President”
Source: John Houston/LinkedIn and John Houston/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023